The report “Expression Vectors Market by Host Type (Bacterial/E.Coli, Mammalian/CHO, Insect/Baculovirus, and Yeast), Application (Therapeutic, Research, and Industrial), End User (Pharmaceutical, Biotechnology, CROs & CMOs, and Academic Research) - Forecast to 2020” provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the expression vectors market along with estimates and forecasts of the revenue and market share analysis.
Browse 99 market data tables and 45 figures spread through 175 pages and in-depth TOC on “Expression Vectors Market by Host Type (Bacterial/E.Coli, Mammalian/CHO, Insect/Baculovirus, and Yeast), Application (Therapeutic, Research, and Industrial), End User (Pharmaceutical, Biotechnology, CROs & CMOs, and Academic Research) - Forecast to 2020"
Early buyers will receive 10% customization on reports.
The expression vectors market is expected to reach $317.1 Million by 2020 from $242.7 Million in 2015, growing at a CAGR of 5.5% from 2015 to 2020.
The report segments the expression vectors market on the basis of host type, application, end user, and region. On the basis of host type, the bacterial expression vectors market is expected to account for the largest share in 2015, closely followed by mammalian expression vectors. The mammalian expression vectors segment is expected to grow at the highest CAGR during the forecast period, owing to the ability of mammalian host systems to carry out complex post-translational modifications, folding, and assembly of recombinant proteins.
Geographically, the market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America is expected to account for the largest share of the expression vectors market in 2015, while Asia is poised to witness the highest growth rate during the forecast period.
Key players in the expression vectors market include Thermo Fisher Scientific, Inc. (U.S.), Promega Corporation (U.S.), Sigma-Aldrich Corporation (U.S.), Agilent Technologies (U.S.), Bio-Rad Laboratories (U.S.), New England Biolabs (U.S.), Merck Millipore (U.S.), QIAGEN (Netherlands), Clontech Laboratories, Inc. (U.S.), DNA2.0 (U.S.), and GenScript USA Inc. (U.S.).
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza,
17304 Preston Road,
Suite 800, Dallas, TX 75252
Email: [email protected]